Skip to main navigation

Skip to Content

Kinnate Investor Navigation

Overview
Press Releases
Events
Publications / Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Stock Information
Investor Resources
- Investor FAQs
- Email Alerts
Media & IR Contact

Price
Change

stock chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Tools

Press Releases

Year

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Feb 14, 2023

Read More

Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference

Feb 06, 2023

Read More

Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director

Jan 26, 2023

Read More

Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

Jan 17, 2023

Read More

Pagination

First page
Previous page
Page 1
Current page 2

Kinnate Footer Legal

Linkedin
Contact
Privacy
Terms of Use

© 2023 Kinnate Biopharma